Drugs / nL-TUBB4-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07222371 | Sep 2025 → Sep 2027 expected | TUBB4A-related neurologic disorder | University of California, San Diego | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06369974 | Sep 2024 → Jun 2026 overdue | disease of genetic or genomic mechanism | Massachusetts General Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nL-TUBB4-001 | “Drug: nL-TUBB4-001; Personalized antisense oligonucleotide” NCT06369974 ↗ |
| Modality | Antisense oligonucleotide | “personalized antisense oligonucleotide (ASO) drug” NCT06369974 ↗ |